Literature for vaniprevir (S29.001 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2014
1. Xue,W., Ban,Y., Liu,H. and Yao,X.
   Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis
   J Chem Inf Model54, 621-633. PubMed  Europe PubMed DOI  I
2013
2. Ali,A., Aydin,C., Gildemeister,R., Romano,K.P., Cao,H., Ozen,A., Soumana,D., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
   Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance
   ACS Chem Biol8, 1469-1478. PubMed  Europe PubMed DOI  I
2012
3. Romano,K.P., Ali,A., Aydin,C., Soumana,D., Ozen,A., Deveau,L.M., Silver,C., Cao,H., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
   The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
   PLoS Pathog8, e1002832-e1002832. PubMed  Europe PubMed DOI  S  I
2011
4. Gottwein,J.M., Scheel,T.K., Jensen,T.B., Ghanem,L. and Bukh,J.
   Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
   Gastroenterology141, 1067-1079. PubMed  Europe PubMed DOI  I
2010
5. Bae,A., Sun,S.C., Qi,X., Chen,X., Ku,K., Worth,A., Wong,K.A., Harris,J., Miller,M.D. and Mo,H.
   Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors
   Antimicrob Agents Chemother54, 5288-5297. PubMed  Europe PubMed DOI  I
6. Liverton,N.J., Carroll,S.S., Dimuzio,J., Fandozzi,C., Graham,D.J., Hazuda,D., Holloway,M.K., Ludmerer,S.W., McCauley,J.A., McIntyre,C.J., Olsen,D.B., Rudd,M.T., Stahlhut,M. and Vacca,J.P.
   MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease
   Antimicrobial Agents Chemother54, 305-311. PubMed  Europe PubMed DOI  I
7. McCauley,J.A., McIntyre,C.J., Rudd,M.T., Nguyen,K.T., Romano,J.J., Butcher,J.W., Gilbert,K.F., Bush,K.J., Holloway,M.K., Swestock,J., Wan,B.L., Carroll,S.S., DiMuzio,J.M., Graham,D.J., Ludmerer,S.W., Mao,S.S., Stahlhut,M.W., Fandozzi,C.M., Trainor,N., Olsen,D.B., Vacca,J.P. and Liverton,N.J.
   Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor
   J Med Chem53, 2443-2463. PubMed  Europe PubMed DOI  I
8. Pompei,M., Di Francesco,M.E., Pesci,S., Koch,U., Vignetti,S.E., Veneziano,M., Pace,P. and Summa,V.
   Novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy
   Bioorg Med Chem Lett20, 168-174. PubMed  Europe PubMed DOI  I
2009
9. Anderson,M.D., Breidinger,S.A. and Woolf,E.J.
   Effect of disease state on ionization during bioanalysis of MK-7009, a selective HCV NS3/NS4 protease inhibitor, in human plasma and human Tween-treated urine by high-performance liquid chromatography with tandem mass spectrometric detection
   J Chromatogr B Analyt Technol Biomed Life Sci877, 1047-1056. PubMed  Europe PubMed DOI  I